A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 105 participants.
Also called NCT06845202
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 105 participants
- Sponsor
- Registry
-
NCT06845202 -
2024-519005-35-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Canada, Chile, Germany, Poland
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06845202. Randomized; triple masking; primary purpose treatment. Start 2025-03-03 (actual); primary completion 2027-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
- Condition
- Obese or Overweight Healthy Volunteers
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- ALN-4324
- Intervention (Drug)
- Placebo
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct06845202- Content hash
de06973b6a1fc846ea2ad74f465428c63a63b841be49d0323c26b2a924fb11ad